BRI3BP and hepatocellular carcinoma: To establish BRI3BP as a clinically actionable prognostic determinant in HCC, we analyzed its association with overall survival (OS); time from diagnosis to death from any cause; disease-free survival (DFS); time from treatment to recurrence or death; and progression-free interval (PFI); time from treatment to progression or death (Fig. 2g and i).